Document is current
Any future updates will be listed below
-
Authors
Ding, Yaowei https://orcid.org/0000-0003-3167-6241
Jiang, Lingling
Wang, Tingting https://orcid.org/0000-0002-3809-2209
Chen, Yuxin
Pan, Yuesong
Li, Xiaotong
Yan, Hongyi
Chen, Weiqi https://orcid.org/0000-0002-2551-9314
Zhang, Guojun https://orcid.org/0000-0003-4911-5784
Wang, Yilong https://orcid.org/0000-0002-3267-0039
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03635749 at ClinicalTrials.govDocuments that mention this clinical trial
Oxidised low-density lipoprotein and adverse outcome in patients with acute mild ischaemic stroke or high-risk TIA: a secondary analysis of the INSPIRES randomised clinical trial
https://doi.org/10.1136/svn-2024-003664
Does the Burden of CSVD Modify the Efficacy of Dual Antiplatelet Therapy?: A Post Hoc Analysis of the INSPIRES Trial
https://doi.org/10.1161/strokeaha.124.049826
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis
https://doi.org/10.1161/strokeaha.124.049246
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
https://doi.org/10.1136/svn-2022-002084
<i>CYP2C19</i> Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke
https://doi.org/10.1161/strokeaha.125.052167
-
Funding
Funding for this research was provided by:
Beijing Laboratory of Oral Health (PXM2021_014226_000041)
Capital’s Funds for Health Improvement and Research (2024-1-2043)
Key R&D Program of China (2017YFC1307900, 2017YFC1307905, 2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505)
National Natural Science Foundation of China (82101358, 82425101)
Beijing Nova Program (20230484336)
- License Information
